Other languages Insulet Corporation

Equities

PODD

US45784P1012

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-10 pm EDT			5-day change	1st Jan Change
192 ^USD	+0.32%		+5.86%	-11.49%

Jun. 06	Transcript : Insulet Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 09:00 AM
May. 30	Redburn Atlantic Initiates Insulet With Buy Rating, $235 Price Target	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Insulet Insider Sold Shares Worth $596,970, According to a Recent SEC Filing	May. 29
Insulet Shares Rise Despite Blue Orca's Short Position	May. 14
STATI UNITI. - I titoli di Wall Street da tenere d'occhio (aggiornamento)	May. 10
EE.UU. - Valores a seguir en Wall Street (actualizado)	May. 10
Novavax, Insulet, Moderna... Les valeurs à suivre aujourd'hui à Wall Street	May. 10
Insulet : manque le consensus pour son bénéfice trimestriel	May. 10
Insulet misses first-quarter profit estimates as marketing costs weigh	May. 09
Insulet Q1 Earnings, Revenue Rise; 2024 Revenue Growth Boosted	May. 09
Insulet Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Insulet Corporation Provides Revenue Guidance for the Second Quarter Ending June 30, 2024	May. 09
Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024	May. 09
China trade heats up, UK rates in view	May. 09
US Equity Markets Close Higher Wednesday as Fed Holds Rates Steady	Mar. 20
Insulet Names Ana Maria Chadwick Finance Chief	Mar. 20
Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024	Mar. 20
Insulet Says Trial Shows Omnipod 5 Insulin Delivery System Superior to Pump Therapy	Mar. 08
Insulet Corporation Presents Positive Results from its First Randomized Controlled Trial Showing Improved Glycemic and Patient-Reported Outcomes in Type 1 Diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5)	Mar. 08
Insulet Corporation to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17Th International Conference on Advanced Technologies & Treatments for Diabetes	Mar. 05
Insulet forecasts weak annual revenue growth; shares drop	Feb. 22
Insulet Q4 Adjusted Earnings, Revenue Increase; Q1, 2024 Revenue Outlook Set	Feb. 22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Insulet Corporation

Equities

PODD

US45784P1012

Other languages

Filters